Fluvoxamine Cuts Long COVID Fatigue in Randomized Trial — And It Costs Pennies

Here is the specific fact that matters: 399 adults. Randomized. Controlled. Placebo-compared. That is not a promising signal or a preliminary hint — that is clinical trial evidence, and it just pointed directly at fluvoxamine, a decades-old antidepressant that costs a fraction of newer experimental therapies. For the tens of millions of people worldwide whose lives have been hollowed out by long COVID fatigue, this is not a small development. Fluvoxamine is already approved, already manufactured at scale, and already understood by the medical community. That matters enormously. New drug pipelines take years and billions of dollars. A repositioned generic can move fast. Physicians can prescribe it today. Patients in low-income countries and underinsured communities — the populations hit hardest by long COVID's lingering burden — can actually afford it. The barrier between this trial result and a patient feeling better is unusually low. Long COVID fatigue is not ordinary tiredness. It is a post-viral syndrome that can leave previously healthy people bed-bound, cognitively impaired, and unable to work for months or years. Until now, the treatment landscape has been largely supportive — manage symptoms, pace activity, wait. A medication showing statistically significant fatigue reduction in a properly powered trial changes that conversation at a fundamental level. Researchers now have a confirmed mechanism worth studying further and a compound worth fast-tracking into clinical practice. The study was published and reported via Science Daily on July 18, 2026. The trial size — 399 participants — gives it genuine statistical weight. This is the kind of result that earns a place in treatment guidelines. For anyone who has watched a family member or friend disappear into long COVID's fog, today's briefing ends with something real: a name, a drug, a trial, and a reason to call their doctor.